Skip to content

Treatment of Dyspepsia (indigestion) with Unani medicine Jawarish Darchini Qawi

An Open-Label, Multicenteric Clinical Validation Study to Evaluate the Efficacy and Safety of Unani Pharmacopoeial Formulation â?? Jawarish Darchini Qawi in Zofe Meda (Dyspepsia)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033637
Enrollment
220
Registered
2021-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K30- Functional dyspepsia

Interventions

Intervention1: Jawarish Darchini Qawi: 5 gms orally twice daily with water after meals for two weeks Control Intervention1: NIL: NIL

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 18-65 years 2. Established diagnosis of non-ulcer dyspepsia (NUD) with gastrointestinal symptoms Abdominal pain Heartburn Acid regurgitation Eructation Nausea and vomiting Abdominal distention Restlessness after meals Belching Loss of appetite/increased appetite Early satiety

Exclusion criteria

Exclusion criteria: 1. Pregnancy and lactation 2. Subjects with severe cardiac, pulmonary, hepatic, renal disease 3. Subjects with palpable abdominal mass 4. Subjects with any other serious concurrent illness or malignancy 5. Subjects with known H. pylori Infection 6. Subjects with Hiatus Hernia 7. Known cases of dysphagia, anaemia/ haematemesis/ melaena 8. Subjects with Diabetes Mellitus 9. Subjects with Inflammatory Bowel Disease; Ulcerative colitis, Crohnâ??s Disease 10. Known cases of Amoebiasis or other Helminthic Diseases 11. Subjects with continuing history of alcohol and / or drug abuse 12. History of long-term medication

Design outcomes

Primary

MeasureTime frame
Improvement in sign and symptoms of Zofe Meda (Dyspepsia)Timepoint: 7days

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: After 2weeks of starting treatment

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026